Connor Clark & Lunn Investment Management Ltd. Acquires New Shares in Avantor, Inc. $AVTR

Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Avantor, Inc. (NYSE:AVTR) in the 2nd quarter, Holdings Channel reports. The institutional investor purchased 388,392 shares of the company’s stock, valued at approximately $3,845,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of AVTR. BlackRock Inc. purchased a new stake in shares of Avantor in the second quarter valued at $695,784,000. Wellington Management Group LLP purchased a new stake in Avantor during the 4th quarter worth about $268,584,000. Engine Capital Management LP increased its position in Avantor by 65.8% during the 1st quarter. Engine Capital Management LP now owns 19,780,830 shares of the company’s stock worth $155,082,000 after purchasing an additional 7,853,018 shares in the last quarter. Barrow Hanley Mewhinney & Strauss LLC acquired a new position in Avantor in the 2nd quarter valued at about $195,386,000. Finally, Morgan Stanley raised its position in shares of Avantor by 179.4% in the fourth quarter. Morgan Stanley now owns 17,468,418 shares of the company’s stock valued at $200,188,000 after buying an additional 11,216,565 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Avantor Stock Performance

Avantor stock opened at $14.60 on Friday. The stock has a market cap of $9.87 billion, a P/E ratio of -17.38, a price-to-earnings-growth ratio of 11.03 and a beta of 0.89. The company has a current ratio of 1.78, a quick ratio of 1.18 and a debt-to-equity ratio of 0.65. The stock has a 50 day moving average of $12.12 and a 200-day moving average of $9.77. Avantor, Inc. has a 52 week low of $7.26 and a 52 week high of $15.93.

Avantor (NYSE:AVTR) last issued its quarterly earnings results on Wednesday, July 29th. The company reported $0.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.19 by $0.02. The business had revenue of $1.69 billion during the quarter, compared to analyst estimates of $1.61 billion. Avantor had a negative net margin of 8.81% and a positive return on equity of 9.92%. The business’s revenue was up .5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.24 earnings per share. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. On average, analysts expect that Avantor, Inc. will post 0.81 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on AVTR. Jefferies Financial Group upgraded shares of Avantor from an “underperform” rating to a “hold” rating and set a $13.00 price objective on the stock in a report on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $13.00 price objective on shares of Avantor in a research note on Thursday, July 30th. Stifel Nicolaus raised their target price on Avantor from $8.00 to $15.00 and gave the company a “hold” rating in a report on Thursday, July 30th. Royal Bank Of Canada upped their price target on Avantor from $9.00 to $14.00 and gave the stock a “sector perform” rating in a report on Thursday, July 30th. Finally, UBS Group set a $8.00 target price on shares of Avantor in a research report on Wednesday, June 24th. Two analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Avantor has a consensus rating of “Hold” and an average target price of $12.00.

Avantor Profile

Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor’s offerings are organized across two primary segments.